Paolo Valsecchi

Paolo Valsecchi

Auto-generated profile, based on publicly available information

Paolo Valsecchi

Department of Psychiatry, Brescia University School of Medicine, Brescia, Italy - University Psychiatric Unit, Brescia University School of Medicine and Brescia Spedali Civili, Brescia, Italy - Department of Mental Health, Brescia Spedali Civili, Brescia, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SBStefano Barlati
Stefano Barlati
GDGiacomo Deste
Giacomo Deste
AGAlessandro Galluzzo
Alessandro Galluzzo
APAnna Paola Perin
Anna Paola Perin
PVPaolo Valsecchi
Paolo Valsecchi
AVAntonio Vita
Antonio Vita
Cognitive impairment is a central feature of schizophrenia and has shown to play a crucial role in the psychosocial function of the disorder. Over the past few years, several cognitive remediation (CR) interventions have been developed for schizophrenia, whose effectiveness has also been widely demonstrated by systematic reviews and meta-analysis studies. Despite these evidences, many questions remain open. In particular, the identification of CR response predictors in patients with schizophrenia is still a topic with equivocal findings and only a few studies have looked for the relationship between CR response or resistance and the biological, socio-demographic, clinical and cognitive features in schizophrenia. The current knowledge on positive or negative response predictors to CR treatment in schizophrenia include: age, duration of illness, premorbid adjustment, baseline cognitive performance, intrinsic motivation, hostility, disorganized symptoms, neurobiological reserve, genetic polymorphisms, the amounts of antipsychotics, the type of CR, etc. The aim of this review is to identify neurobiological, psychopathological, cognitive, and functional predictors of CR response or resistance in schizophrenia, taking into account both cognitive and functional outcome measures. The information obtained could be very useful in planning integrated and personalized interventions, also with a better use of the available resources.

20 December 2018 in Journal of Attention Disorders
Verified
Journal Article
Closed access
PVPaolo Valsecchi
Paolo Valsecchi
GNGabriele Nibbio
Gabriele Nibbio
JRJennifer Rosa
Jennifer Rosa
ETElena Tamussi
Elena Tamussi
CTCesare Turrina
Cesare Turrina
AVAntonio Vita
Antonio Vita
Objective: ADHD remains a largely underdiagnosed disorder in Europe and especially in Italy. Aims of the present study were to assess the prevalence of ADHD and its clinical and demographic correlates in a large sample of Italian outpatients. Method: 634 outpatients accessing psychiatric services were assessed with the Mini-International Neuropsychiatric Interview (MINI) Plus V. 5.0.0 interview and the Adult ADHD self-report Scale Symptoms Checklist (ASRS)-V 1.1 Short Form. Patients positive to the ASRS-V 1.1 were assessed with the Diagnostic Interview for ADHD in Adults (DIVA) 2.0. Results: Of the total patients’ sample, 81 (12.8%) were positive on the ASRS-V 1.1. After performing the DIVA 2.0, 44 patients (6.9%) met the criteria for Adult ADHD. Significant clinical and demographic differences between ADHD positive and negative groups were found. Conclusion: The prevalence and correlates of ADHD comorbidity in our outpatient psychiatric population were comparable to those found in other high-income countries. Considering the prevalence of ADHD and its impact on functioning, implementing specific knowledge on this subject is needed.

17 April 2007 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
CMChiara Magri
Chiara Magri
RGRita Gardella
Rita Gardella
Stefano BarlatiStefano Barlati
Stefano Barlati
PVPaolo Valsecchi
Paolo Valsecchi
LCLuisella Bocchio Chiavetto
Luisella Bocchio Chiavetto
SBSergio Barlati
Sergio Barlati

31 January 2008 in Schizophrenia Research
Verified
Journal Article
Closed access
ESEmilio Sacchetti
Emilio Sacchetti
PVPaolo Valsecchi
Paolo Valsecchi
GPGiovanni Parrinello
Giovanni Parrinello

15 February 2022 in Psychiatry Research
Verified
Journal Article
Closed access
PVPaolo Valsecchi
Paolo Valsecchi
GNGabriele Nibbio
Gabriele Nibbio
JRJennifer Rosa
Jennifer Rosa
AVAntonio Vita
Antonio Vita

1 November 2019 in Rivista di Psichiatria
Verified
Journal Article
Closed access
PVPaolo Valsecchi
Paolo Valsecchi
SBStefano Barlati
Stefano Barlati
AGAndrea Garozzo
Andrea Garozzo
GDGiacomo Deste
Giacomo Deste
GNGabriele Nibbio
Gabriele Nibbio
AVAntonio Vita
Antonio Vita
SUMMARY. Poor adherence to treatment remains a major problem in the management of patients with schizophrenia. In the 60s, first generation antipsychotics in depot formulation have been introduced on the market with the aim to improve adherence to therapy. However, the limited effectiveness on negative symptoms and the tendency to induce extrapyramidal side effects has limited their use. Currently there are five second-generation antipsychotic long-acting formulations and the use of these drugs has definitely changed perspective: they are no more restricted as compounds intended to improve compliance, but they can be considered first-line drugs with proven efficacy and good tolerability. In this narrative review the efficacy and tolerability of paliperidone palmitate, as well as the economic impact of the use of this particular molecule, have been evaluated in the short- and long-term treatment of schizophrenia. Taking into account the results of different studies, paliperidone, especially in his long-acting formulation, can be considered a viable and effective treatment for patients with schizophrenia, both in the short- and in the long term.